Hydroxychloroquine + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction, Acute Coronary Syndrome, Inflammation, Hydroxychloroquine, Antirheumatic Agents, Cardiovascular Diseases
Trial Timeline
Feb 1, 2016 → Dec 31, 2019
NCT ID
NCT02648464About Hydroxychloroquine + Placebo
Hydroxychloroquine + Placebo is a approved stage product being developed by Orion Corporation for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02648464. Target conditions include Myocardial Infarction, Acute Coronary Syndrome, Inflammation.
What happened to similar drugs?
9 of 20 similar drugs in Myocardial Infarction were approved
Approved (9) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02648464 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction